Onconetix, Inc. Files 8-K with Exhibit Details

TL;DR

ONCO files 8-K, updates on financials & exhibits. Former names noted.

AI Summary

Onconetix, Inc. filed an 8-K on September 3, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing also notes the company's former names, Blue Water Biotech, Inc. and Blue Water Vaccines Inc., with name change dates in 2023 and 2019, respectively. The principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio.

Why It Matters

This 8-K filing provides an update on Onconetix, Inc.'s corporate reporting, including financial statements and exhibits, which are crucial for investors to assess the company's current status.

Risk Assessment

Risk Level: low — This filing is primarily procedural and informational, with no immediate financial or operational risks indicated.

Key Players & Entities

• Onconetix, Inc. (company) — Registrant
• Blue Water Biotech, Inc. (company) — Former company name
• Blue Water Vaccines Inc. (company) — Former company name
• September 3, 2024 (date) — Date of report
• 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
• $4.00 — e a minimum price per share of at least $4.00 (the " Minimum Price Rule "). Suppleme
• $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on Nasd
• $2,500,000 — sted companies to maintain a minimum of $2,500,000 in stockholders' equity for continued l
• $1,404,476 — filed with the SEC on April 1, 2024 was $1,404,476, and as of the date of the notice, we d
• $35 million — value of listed securities of at least $35 million or (ii) net income from continuing oper
• $500,000 — from continuing operations of at least $500,000 in the fiscal year ended December 31, 2
• $5,000,000 — e Rule, minimum stockholders' equity of $5,000,000, and minimum market value of publicly h
• $15,000,000 — et value of publicly held securities of $15,000,000. In order to assist with satisfying app

Filing Documents

• ea0213181-8k_onconetix.htm (8-K) — 57KB
• 0001213900-24-075008.txt ( ) — 234KB
• onco-20240903.xsd (EX-101.SCH) — 3KB
• onco-20240903_lab.xml (EX-101.LAB) — 33KB
• onco-20240903_pre.xml (EX-101.PRE) — 22KB
• ea0213181-8k_onconetix_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On July 30, 2024, the Company received a letter from Nasdaq staff (the " Nasdaq Letter ") stating that the staff had determined that the Company's acquisition of Proteomedix AG constitutes a business combination that results in a "Change of Control" pursuant to Nasdaq Listing Rule 5110(a), and that, as a result, the Company will be required to satisfy all of Nasdaq's initial listing criteria and to complete Nasdaq's initial listing process prior to the conversion of the Series B Preferred Stock, or other material changes triggering a change of control. Among other things, Nasdaq's initial listing criteria require a minimum price per share of at least $4.00 (the " Minimum Price Rule "). Supplement to the Definitive Proxy Statement On August 1, 2024, Onconetix, Inc. (the "Company") filed a definitive proxy statement (the "Definitive Proxy Statement") for the solicitation of proxies in connection with an annual meeting of the Company's stockholders to be held on September 5, 2024 (the "Annual Meeting") to consider and vote on, among other proposals, an amendment that would authorize, but not obligate, the board of directors (the "Board") to amend the Company's Certificate of Incorporation to effect a reverse stock split of the outstanding and treasury shares of Company common stock ("Common Stock") at a ratio in the range of 1-for-30 to 1-for-60, which ratio would be subject to the Board's discretion following stockholder approval (the "Reverse Stock Split"). In view of the Nasdaq Letter, the Company has determined to supplement certain information contained in the Definitive Proxy Statement to provide updates with respect to the Company's Nasdaq compliance status, the reasons for the Reverse Split Proposal, and related risks. SUPPLEMENT TO THE DEFINITIVE PROXY STATEMENT OF ONCONETIX, INC. Dated September 3, 2024 The Company is providing additional information to its stockholders, as described in this supplement to the Definitive Proxy

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Certain risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking indicated from time to time in the definitive proxy statement to be delivered to the Company's stockholders, including those set forth under "Risk Factors" therein, and other documents filed to be filed with the U.S. Securities and Exchange Commission (" SEC ") by the Company. Additional Information and Where to Find It The Company has filed with the SEC a definitive proxy statement (the " Definitive Proxy Statement ") in connection with the Annual Meeting and, beginning on or about August 2, 2024, mailed the Definitive Proxy Statement and other relevant documents to its stockholders as of the July 31, 2024 record date for the Annual Meeting. The Compa

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 6

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. September 3, 2024 By: /s/ Karina Fedasz Name: Karina Fedasz Title: Interim Chief Financial Officer 7

View Full Filing

View this 8-K filing on SEC EDGAR